National Cancer Institute - NCI Division of Cancer Treatment and ...

C U R R E N T F U N D I N G O P P O R T U N I T I E S
Phased Application Awards in
Cancer Prognosis and Prediction
Program Announcement:
PA-04-102: http://grants.nih.gov/grants/
guide/pa-files/PA-04-102.html
(expiration date 11/2/2006)
Contacts:
Tracy Lively, Ph.D.
301-496-1591, livelyt@mail.nih.gov
Magdalena Thurin, Ph.D.
301-496-1591, thurinm@mail.nih.gov
James V. Tricoli, Ph.D.
301-496-1591, tricolij@mail.nih.gov
An increasing number of publications
have described new molecules, new
patterns of gene expression, and new
aspects of tumor cell growth that seem
to be correlated with known prognostic
factors. However, studies that go beyond
the exploratory stage of developing a
new diagnostic test require large numbers
of patient samples with associated clinical
data. They also need an efficient assay
technique and a great deal of statistical
input. Such tools could improve clinical
decision-making in the care of cancer
patients.
This CDP-sponsored program is accelerating
the translation of new discoveries into
clinical practice by allowing investigators
to use new diagnostic strategies to solve
clinical problems. By providing up to five
years of support for a first phase grant
(R21) for technical development and a
second phase grant (R33) for application
and evaluation of clinical utility, CDP will
enable investigators to evaluate the utility
and pilot the application of new strategies
for determining prognosis or predicting
response to therapy.
34 ■ P R O G R A M A C C O M P L I S H M E N T S 2 0 0 6
Exploratory Studies in
Cancer Detection, Diagnosis,
and Prognosis
Program Announcement:
PA-05-165: http://grants.nih.gov/grants/
guide/pa-files/PA-05-165.html
(expiration date 11/2/2008)
Contact:
James V. Tricoli, Ph.D.
301-496-1591, tricolij@mail.nih.gov
Advances in the understanding of
basic cancer biology and the development
of powerful molecular technologies
are leading to the identification of many
new abnormalities in precancerous and
cancer cells. New biomarkers and laboratory
assays are needed to screen patients
for cancer and assess their risk. These
biomarkers could also be used to assess
disease prognosis and response to
cancer treatments, especially new
treatments.
The major goal of this CDP initiative is
to promote the initial evaluation of new
molecular or cellular characteristics of
premalignant cells or tumors or the development
of assays that will be useful for
cancer detection, diagnosis, and prognosis.
Using the exploratory/developmental
grant (R21) mechanism, this initiative will
provide up to two years of support for
translational studies that identify promising
new means for cancer detection and
diagnosis and provide the initial, critical
information needed to decide whether
potential clinical utility justifies further
investment.